In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will PDUFA V be a 'damned if it does, damned if it doesn't' scenario for US FDA?

This article was originally published in SRA

Executive Summary

Instead of being praised for speeding new treatments to patients or advancing medical innovation, the US Food and Drug Administration has come in for sharp criticism for failing to do enough to ensure patient safety, and this has resulted in the agency shifting to a more cautious, risk-averse posture in recent years, asserted Jonathan Leff, managing director of New York-based equity investment firm Warburg Pincus1,2.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts